Cell surface CD43 determination improves diagnostic precision in late B-cell diseases

Area of Science:

• Immunology
• Hematology
• Medical Diagnostics

Background:

• B-cell leukaemias exhibit variability, necessitating refined diagnostic approaches.
• Immunological marker panels are crucial for accurate classification.
• Distinguishing chronic lymphoid leukaemia (CLL) from non-CLL lymphoma is clinically important.

Purpose of the Study:

• To evaluate the diagnostic value of CD43 in combination with established markers for B-cell leukaemias.
• To improve the accuracy of differentiating CLL from lymphoma using a multivariate statistical approach.

Main Methods:

• A statistical multivariate approach was applied to a preliminary sample of 100 B-leukaemias.
• The study analyzed a panel including CD43, CD5, CD23, CD79b, FMC7, CD22, and surface immunoglobulin.
• The marker panel's discriminatory power was assessed in a control sample of 74 B-leukaemias.

Main Results:

• CD43 demonstrated high statistical significance (P < 0.00001) in differentiating B-cell leukaemias.
• Including CD43 in marker panels improved diagnostic accuracy to 98.6% in a control sample.
• The combination of markers, particularly with CD43, effectively distinguished CLL from lymphoma.

Conclusions:

• CD43 is a highly effective marker for refining the diagnosis of B-lymphoproliferative disorders.
• The inclusion of CD43 significantly enhances the classification accuracy of B-cell leukaemias.
• This approach facilitates more precise diagnosis and sub-classification of lymphoid malignancies.